CYP2C9 and Hypoglycemia: Since these drugs are metabolized by highly polymorphic enzymes such as CYP2C9 and CYP2C19, variability in enzyme function can lead to reduced drug efficacy and the occurrence of ADRs, including severe secondary hypoglycemia [18].